NEO
HealthcareNeoGenomics, Inc.
$12.08
+$0.32 (+2.72%)
Jan 5, 2026
Price History (1Y)
Analysis
NeoGenomics, Inc. is a healthcare company operating in the diagnostics and research industry, with a market capitalization of $1.56 billion. The company has a significant presence, employing approximately 2200 individuals. NeoGenomics' revenue (TTM) is reported to be $709.16 million. The financial health of NeoGenomics appears mixed. While it reports a gross margin of 43.4%, the company's operating and profit margins are negative at -8.1% and -16.0%, respectively. The net income (TTM) is -$113,468,000. Additionally, the return on equity (ROE) and return on assets (ROA) are both negative at -13.0% and -3.0%, respectively. The company's debt-to-equity ratio is 48.95, while it has $164.12 million in cash. In terms of valuation, NeoGenomics' forward P/E ratio is 67.74, while its price to book ratio is 1.86. The revenue growth (YoY) is reported to be 11.9%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About NeoGenomics, Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Visit website →Key Statistics
- Market Cap
- $1.56B
- P/E Ratio
- N/A
- 52-Week High
- $19.11
- 52-Week Low
- $4.72
- Avg Volume
- 2.95M
- Beta
- 1.57
Company Info
- Industry
- Diagnostics & Research
- Exchange
- NCM
- Country
- United States
- Employees
- 2,200